Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
Relate News
2/17/2022
Review of Chinese Pharma Deals, R&D and Regulatory Developments in 202...
2/17/2022
Chinese Pharmaceutical Cross-Border M&A in 2022 (PharmExec)
2/16/2022
FDA Places Phase 1 Trial of Legend's Early-stage CAR-T on Hold
2/16/2022
SciNeuro and Alamar Collaborate to Discover Novel Therapeutic Antibodi...
2/16/2022
Organon Acquires Bayer's Contraceptive Products Marvelon and Mercilo...
2/16/2022
USTR: China Falling Short on WTO Compliance and New Trade Tools Are N...
2/16/2022
Information Collection on the 7th VBP Officially Initiated by the JPO
2/16/2022
CDE Issues the Technical Guidelines on Clinical Trial of Antiviral The...
2/15/2022
Snapshot of MNC Pharma's China Performance in 2021
2/15/2022
Moderna Announces Plan to Expand Footprint in Asia with Four Additiona...
2/15/2022
China Faces Fresh Health Crisis as Experts Discover Alarming Heart Con...
2/15/2022
ChinaBio Partnering Forum Acquired by EBD Group/Informa
2/15/2022
Lacking Revenue, Lepu Biopharma Chases IPO to Revive War Chest (The Ba...
2/14/2022
Chinese Drug Developers Look to Enter the U.S. Market through Out-lice...
2/14/2022
Bloomberg: China's Approval of Pfizer Pill Opens Door to Ending Its 'C...
2/14/2022
Takeda Vows to Expand Business and Investments in China
2/14/2022
Chinese CDMO Asymchem to Expand in the U.S. thru Acquisition of Snapdr...
2/14/2022
NHC Reorganizes, Integrating Relevant Jurisdictions and Departments wi...
2/13/2022
China Approves Pfizer's Covid Drug Paxlovid Conditionally
2/13/2022
State Council's Policy Briefing Confirms Accelerated Expansion of Cent...
2/13/2022
Innovent's Setback Warns Peers Prioritizing Pricing Not Good Tactic in...
2/11/2022
EdiGene and Neukio Enter Collaboration to Develop Next-Generation Immu...
2/11/2022
AKSO and Huadong Medicine Enter Strategic Collaboration to Develop/Com...
2/11/2022
NMPA Issues the List of Reference Formulations for GQCE Studies (51st ...
2/11/2022
Drug R&D and Product Registration News Digest February 2022 (1)
2/10/2022
AstraZeneca Reports Q4 and FY 2021 Performance, China Revenue Surging ...
2/10/2022
CDE Issues the Q&As on Issues Related to Pharmaceutical Research and E...
2/10/2022
GSK Won Chinese Approval of Benlysta (belimumab) for Adult Patients wi...
2/10/2022
U.S. FDA Panel Recommends Additional Trial for Lilly/Innovent Lung Ca...
2/10/2022
China Is the Focus of AZ's Earnings Call for Q4 and FY 2021, BMI Fraud...
Page:
149
/
774
Total number of articles:
23208
:
[First]
[<<]
[147]
[148]
[149]
[150]
[151]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit